Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma

Nivolumab potentially superior to standard chemo in advanced melanoma

Targeted therapy for iodine-refractory thyroid cancer

Young oncologists bridging the gap between translational and clinical cancer research

PD-L1 protein a possible immunotherapy target in mesothelioma

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

EORTC and the management of clinical trial data

Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Phase III trial results raise questions about the future of lung cancer vaccination

Little benefit for gefitinib-resistant lung cancer when continuing the drug with chemotherapy